Lutetium-177 (177Lu) is a late entrant into the nuclear medicine therapy
arena but is expected to become one of the most widely used therapeutic radionuclides.
This paper analyses the reason for the increasing preference of 177Lu as a therapeutic
radionuclide. While the radionuclidic properties favor its use for several therapeutic
applications, the potential for large scale production of 177Lu is also an important aspect
for its acceptability as a therapeutic radionuclide. This introductory discussion also summarizes some developing
clinical uses and suggested future directions for applications of 177Lu.
Keywords: Antibodies, bone pain palliation, isotope production, Lutetium-177, peptides, targeted radionuclide therapy, therapeutic
Rights & PermissionsPrintExport